This genomic event results in the fusion of the ERG proto-oncogene with the androgen-driven promoter of the TMPRSS2, setting the transcription of the former under hormonal affection and resulting in its over-expression in cancer cells [5]. This evidence concerns the gene TMPRSS2 and cancer.